Find our consolidated key figures and our financial calendar below, or go directly to our financial reports and SEC filings
| Date | Details |
|---|---|
| February 24, 2027 | Full-year results 2026 |
| March 25, 2027 | Annual report 2026 |
| April 27, 2027 | Annual General Shareholders’ Meeting |
| May 3, 2027 | First quarter results 2027 |
| August 4, 2027 | Half-year results 2027 |
| November 3, 2027 | Third quarter results 2027 |
Annual Report? Half year report? All financial reports, right here!
| (thousands of €, if not stated otherwise) | Nine months ended September 30, 2026 | Nine months ended September 30, 2025 | Year ended December 31, 2025 |
| Income statement | |||
| Supply revenues | 17.726 | 29.332 | 29.924 |
| Collaboration revenues | 8.443 | 182.094 | 1.082.324 |
| Total net revenues | 26.169 | 211.426 | 1.112.248 |
| Cost of sales | (17.621) | (29.281) | (29.736) |
| R&D expenses | (82.498) | (351.909) | (459.421) |
| S&M, G&A expenses | (76.601) | (109.017) | (153.433) |
| Impairment of the cell therapy activities | – | (204.753) | (228.112) |
| Other operating income | 2.165 | 21.374 | 53.493 |
| Operating profit/loss (-) | (148.386) | (462.160) | 295.039 |
| Net financial results | 156.173 | (20.124) | 5.832 |
| Taxes | (245) | 19.287 | 18.621 |
| Net profit/loss (-) from continuing operations | 7.542 | (462.997) | 319.492 |
| Net profit from discontinued operations, net of tax | 6.388 | 1.735 | 1.392 |
| Net profit/loss (-) | 13.930 | (461.262) | 320.884 |
| Balance sheet | |||
| Cash and cash equivalents | 94.655 | 64.458 | 87.868 |
| Financial investments | 2.088.484 | 2.985.656 | 2.910.180 |
| R&D incentives receivables | 126.347 | 149.339 | 157.870 |
| Assets | 3.294.568 | 3.511.914 | 3.406.518 |
| Shareholders’ equity | 3.232.762 | 2.446.963 | 3.235.868 |
| Deferred income | 33 | 896.431 | 32 |
| Other liabilities | 61.773 | 168.520 | 170.618 |
| CASH FLOW | |||
| Operational cash burn (*) | (97.185) | (145.129) | (189.141) |
| Cash flow used in operating activities | (152.143) | (209.995) | (257.456) |
| Cash flow generated from investing activities | 195.328 | 216.191 | 288.814 |
| Cash flow used in financing activities | (42.919) | (2.868) | (3.273) |
| Increase in cash and cash equivalents | 266 | 3.328 | 28.085 |
| Effect of currency exchange rate fluctuation on cash and cash equivalents | 6.521 | (3.109) | (4.456) |
| Cash and cash equivalents at the end of the period | 94.655 | 64.458 | 87.868 |
| Financial investments at the end of the period | 2.088.484 | 2.985.656 | 2.910.180 |
| Total financial investments and cash and cash equivalents at the end of the period | 2.183.139 | 3.050.114 | 2.998.048 |
| FINANCIAL RATIOS | |||
| Number of shares issued at the end of the period | 65.897.071 | 65.897.071 | 65.897.071 |
| Basic and diluted earnings/loss (-) per share | 0,21 | (7,00) | 4,87 |
| Share price at the end of the period (in €) | 26,42 | 29,16 | 28,00 |
(*)The operational cash burn (or operational cash flow if this liquidity measure is positive) is equal to the increase or decrease in the cash and cash equivalents (excluding the effect of exchange rate differences on cash and cash equivalents), minus:
the cash used for other liabilities related to the acquisition or disposal of businesses, if any, included in the net cash flows generated from/used in (-) operating activities.
the net proceeds, if any, from share capital and share premium increases, and the cash used for the purchase of own shares, included in the net cash flows generated from/used in (-) financing activities
the net proceeds or cash used, if any, related to the acquisition or disposal of businesses; the acquisition of financial assets held at fair value through other comprehensive income; the movement in restricted cash and movement in financial investments, if any, the cash advances and loans given to third parties, if any, included in the net cash flows generated from/used in (-) investing activities
SEC filings are the official documents we submit to the U.S. Securities and Exchange Commission (SEC). They contain financial and non-financial information essential for regulatory compliance and transparency.